Radioactive treatment for advanced kidney cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a radioactive drug called Lu-177 PSMA to see if it can help people with advanced kidney cancer that has not responded to other treatments. It aims to slow the cancer's growth and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your kidney cancer has gotten worse even after trying at least two different treatments (or you cannot take those treatments for medical reasons).
- Your doctor expects you to live at least 3 more years.
- You are generally able to take care of yourself (scored 2 or less on a standard activity scale).
- You do not have another active cancer, are not pregnant or breastfeeding, and have not had radioactive treatment before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
This study tests a radioactive medicine (called 161Tb-PSMA) that delivers radiation directly to kidney cancer cells that have a specific marker (PSMA). It is for people whose kidney cancer has spread and has not responded to at least two prior treatments. The goal is to see if this new therapy can help shrink the cancer.
This early-phase study tests a cancer medicine that uses radiation to target prostate cancer cells that carry a specific marker (PSMA). It may help people whose metastatic prostate cancer has stopped responding to hormone therapy and/or chemotherapy.
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
This study tests a new radioactive drug (177Lu-PSMA-137) that targets a marker on prostate cancer cells called PSMA. It aims to see if this treatment is safe and effective for men with advanced prostate cancer that has spread and stopped responding to standard treatments.
This study tests a radioactive drug called Lu-PSMA-617 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug targets a protein on cancer cells to deliver radiation directly to the tumor.
Hear when a new Metastatic Renal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.